Novel and validated titrimetric method for determination of selected angiotensin-II-receptor antagonists in pharmaceutical preparations and its comparison with UV spectrophotometric determination  by Patil, Shrikant H. & Janjale, Minakshi V.
Contents lists available at ScienceDirect
www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis 2012;2(6):470–4772095-1779 & 2012 X
http://dx.doi.org/10.1
nCorresponding au
fax: þ91 25 32580250
E-mail addresses:
sallu.min98@gmail.c
Peer review under r
Academy of Medicalwww.sciencedirect.comORIGINAL ARTICLE
Novel and validated titrimetric method for determination
of selected angiotensin-II-receptor antagonists in
pharmaceutical preparations and its comparison
with UV spectrophotometric determinationShrikant H. Patila,n, Minakshi V. JanjalebaDepartment of Quality Assurance Techniques, N.D.M.V.P Samaj’s College of Pharmacy, Gangapur Road,
Nasik 422002, Maharashtra, India
bDepartment of Pharmaceutics, S.S.J.I.P.E.R, Jamner 424206, Maharashtra, India
Received 6 December 2011; accepted 30 March 2012
Available online 9 April 2012KEYWORDS
Angiotensin-II-receptor
antagonists;
Titrimetric assay;
UV spectrophotometry;
Validationi’an Jiaotong Univ
016/j.jpha.2012.03
thor. Tel.: þ91 25
.
patilshrikant2010@
om (S.H. Patil)
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Sciences and ChinesAbstract A novel and simple titrimetric method for determination of commonly used angiotensin-II-receptor
antagonists (ARA-IIs) is developed and validated. The direct acid base titration of four ARA-IIs, namely
eprosartan mesylate, irbesartan, telmisartan and valsartan, was carried out in the mixture of ethanol:water (1:1)
as solvent using standardized sodium hydroxide aqueous solution as titrant, either visually using phenolphtha-
lein as an indicator or potentiometrically using combined pH electrode. The method was found to be accurate
and precise, having relative standard deviation of less than 2% for all ARA-IIs studied. Also, it was shown that
the method could be successfully applied to the assay of commercial pharmaceuticals containing the above-
mentioned ARA-IIs. The validity of the method was tested by the recovery studies of standard addition to
pharmaceuticals and the results were found to be satisfactory. Results obtained by this method were found to be
in good agreement with those obtained by UV spectrophotometric method. For UV spectrophotometric
analysis ethanol was used as a solvent and wavelength of 233 nm, 246 nm, 296 nm, and 250 nm was selected for
determination of eprosartan mesylate, irbesartan, telmisartan, and valsartan respectively. The proposed
titrimetric method is simple, rapid, convenient and sufﬁciently precise for quality control purposes.
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tute of Materia Medica, Chinese
e Pharmaceutical Association.1. Introduction
Many of the active components of pharmaceutical prepara-
tions are of organic origin and contain acidic or basic groups.
Such compounds can be successfully determined in their
pharmaceutical preparations using titrimetric methods. The
purpose of this work was to develop a simple, accurate,
reproducible and rapid titrimetric method for the determina-
tion of commonly used angiotensin-II-receptor antagonistslsevier B.V. All rights reserved.
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telmisartan (III) and valsartan (IV), and applying it to the
pharmaceutical dosage forms. These compounds contain
either carboxylic acid group or tetrazole ring or both which
act as an acidic centre and form the basis for acid–base
reactions during titration. The structural formulae of these
ARA-IIs are given in Fig. 1.
These ARA-IIs are safe and effective agents in the treat-
ment of hypertension and heart failure, either alone or in
conjunction with diuretics. They have been proposed as
alternatives to the more traditional angiotensin converting
enzyme (ACE) inhibitors because they selectively block the
angiotensin type 1 (AT1) receptor, which is responsible for
vasoconstriction, and salt and water retention. The angioten-
sin type 2 (AT2) receptor, which is thought to have cardio-
protective effects and inhibitory effects on growth, is left
unaffected [1–6].
Several methods that are reported for ARA-IIs compounds
estimation include enzyme-linked immunosorbent assays
(ELISAs) for the determination of telmisartan in human
blood plasma [7], spetroﬂuorimetric for the determination of
valsartan in human urine [8], colorimetric method [9], and
UV-derivative spectrophotometric [10] for the determination
of ARA-II in bulk and in tablets. Tatar and Saglik [11]
compared UV- and second derivative-spectrophotometric and
high-performance liquid chromatographic methods for the
determination of valsartan in pharmaceutical formulation.
Also, capillary electrophoresis (CE), capillary electrochroma-
tography (CEC), micellar electrokinetic capillary chromato-
graphy (MEKC) and capillary zone electrophoresis (CZE)
methods have also been reported [12–16]. High-performance
liquid chromatography has been the major technique used in
the determination of these compounds in different matrices
with UV [17–24], ﬂuorimetric [25–27] or mass spectrometry
(MS) detections [28–30]. Validated methods which allow the
determination of a single drug [31–39] or combination of
ARA-IIs with hydrochlorothiazide or some of their metabo-
lites [40–43] in urine, plasma and in pharmaceutical formula-
tions [44] have also been published.
Although chromatographic techniques have been suggested
for the determination of ARA-IIs, it requires high skilful
operator and expensive instrument. In addition, most of theFigure 1 Structural formulae of angiotensin-II-receptor antago-
nists: (I) Eprosartan mesylate, (II) Irbesartan, (III) Telmisartan
and (IV) Valsartan.described procedures require expensive instrumental setup. So,
there is a need to develop a simple, reliable, rapid and
economical method for the determination of ARA-IIs in
pharmaceuticals.
No titrimetric method for determination of ARA-IIs has
been found in literature. In this paper, the validated titrimetric
method is described for the determination of ARA-IIs in
pharmaceuticals. The method is based on the titration of the
drug solution in neutral ethanol:water mixture (1:1) with
aqueous NaOH to a phenolphthalein end point or potentio-
metric equivalence point. In this paper the proposed titrimetric
method is a very simple technique and adoptable for routine
analysis to determine the content of ARA-IIs at milligram
level in the quality control laboratories.
Because of unavailability of pharmacopial method for some
of these ARA-IIs, UV spectrophotometric method has been
developed for statistical comparison with results obtained by
proposed titrimetric method. A comparison of results obtained
by the proposed titrimetric method and those obtained by UV
method shows good statistical correlation.2. Materials and methods
2.1. Apparatus
A Jenway 3020 digital pH meter equipped with a combined
pH-electrode was used throughout the study. All titrations
were carried out manually. A shimadzu UV–visible recording
spectrophotometer (model UV2501 PC) with 1 cm matched
quartz cells was used for spectrophotometric analysis.
2.2. Reagents and materials
Eprosartan mesylate, valsartan, and telmisartan were obtained
from Glenmark Pharmaceutical Ltd. Sinnar, Nasik, India; and
irbesartan was obtained from Cadila Healthcare Ltd., Ahmeda-
bad, India. These ARA-IIs were chemically pure laboratory
working standards having purities of 99.8%, 99.4%, 99.6% and
99.3%. Sodium hydroxide, ethanol, potassium hydrogen phtha-
late, and phenolphthalein powder were obtained from Merck,
India and S.D’s Lab Chem & Industries, Bombay. Teveten
(eprosartan mesylate), Karvea (irbesartan), Telsartan (telmisar-
tan) and Diovan (valsartan) tablets were obtained from a local
pharmacy. All chemicals were of analytical reagent grade unless
otherwise stated, and doubly distilled deionised water was used
throughout.
Sodium hydroxide (0.01 M): Accurately 0.2 g of the pure
NaOH (Merck, India) was dissolved in doubly distilled water.
The solution was made up to 500 mL with the same water and
standardized [45].
Phenolphthalein indicator (0.5%): It was prepared by dis-
solving 500 mg of the pure phenolphthalein powder (S.D’s
Lab Chem & Industries, Bombay) in 50 mL alcohol and
diluting to 100 mL with doubly distilled water.
2.3. Procedures
2.3.1. Potentiometric titration
Accurately weighed quantities (2.0–10.0 mg) of four ARA-IIs,
namely eprosartan mesylate, irbesartan, telmisartan and
S.H. Patil, M.V. Janjale472valsartan, were dissolved separately in 20 mL mixture (1:1) of
ethanol and water, depending upon their molar weights.
Ethanol should be previously neutralized to phenolphthalein
solution. All the assay solutions were prepared prior to
titrations directly in a titration cell, and titrated with standar-
dized sodium hydroxide aqueous solution using potentio-
metric titration with a combined platinum ring electrode.
Near the equivalence point, titrant was added in 0.05 mL
increments. After each addition of titrant, the solution was
stirred magnetically for 30 s and the steady potential was
noted. The addition of titrant was continued until no sig-
niﬁcant change in potential on further addition of titrant. The
equivalence point was determined by applying the graphical
method. The amount of the drug in the measured aliquot was
calculated from:
Amount ðmgÞ ¼VMwR=n
where V is the volume of NaOH required, mL; Mw is the
relative molecular mass of the drug; R is the molarity of
NaOH and n is the number of moles of NaOH reacting with
each mole of the drug.
2.3.2. Visual titration
Accurately weighed quantities (2.0–10.0 mg) of four ARA-IIs,
namely eprosartan mesylate, irbesartan, telmisartan and val-
sartan, were dissolved separately in a mixture of 10 mL of
water and 10 mL of neutral ethanol depending upon their
molar weights. All the assay solutions were titrated with
standardized sodium hydroxide aqueous solution using 2–4
drops of 0.5% phenolphthalein indicator to a pink colour end
point. The amount of the drug in the measured aliquot was
calculated as described under potentiometric titration.
2.3.3. Titrimetric determination of ARA-IIs from
pharmaceutical preparations
Twenty tablets were weighed, and their average weights were
calculated. All the tablets were ﬁnely powdered and the
required amounts of these powders were dissolved in a mixture
of 10 mL of water and 10 mL of ethanol. The mixture was
sonicated for 5 min and ﬁltered using Whatmann No 42 ﬁlter
paper. A suitable aliquot was next subjected to analysis by
potentiometry and visual titration method as described earlier.
The titrations were repeated for different amounts of each
ARA-II and pharmaceutical preparation.
2.3.4. UV-spectrophotometric method
For obtaining calibration curve for UV-method, a series of
solutions were prepared for each ARA-II within their Beer–
Lambert’s range of concentration as shown in Table 1, by
diluting the respective stock ARA-II solution (0.1 mg/mL inTable 1 Summary of optical characteristics and validation param
Parameters Eprosartan mesylate Irbe
Lambda max (nm) 233 246
Beer’s law limit (range) (mg/mL) 6–36 2–36
Correlation coefﬁcient (r7S.D.) 0.99970.690 0.99
Regression equation Y¼0.056xþ0.023 Y¼
LOD (mg/mL) 0.4142 0.51
LOQ (mg/mL) 1.2552 1.54ethanol) with ethanol in volumetric ﬂasks (10 mL). The
absorbance of each solution was determined at respective
lambda max of the drug as shown in Table 1 against ethanol
as blank. A calibration curve was prepared by plotting
absorbance versus concentration for each ARA-II. Absorp-
tion spectra of ARA-IIs are given in Fig. 2.
2.3.5. UV spectroscopic determination of ARA-IIs from
pharmaceutical preparations
Twenty tablets were weighed, and their average weights were
calculated. All the tablets were ﬁnely powdered and the
required amounts of these powders were dissolved in 20 mL
of ethanol. The mixture was sonicated for 5 min and ﬁltered
using Whatmann No 42 ﬁlter paper. After suitable dilution,
absorbance was recorded against the blank at respective
lambda max of drug as shown in Table 1.
2.4. Method validation
Both potentiometric and UV spectroscopic methods were
validated in compliance with ICH guidelines. The following
parameters were validated.
2.4.1. Precision
The precision of the potentiometric and UV spectroscopic
methods was evaluated in terms of intermediate precision
(intra-day and inter-day). Three different amounts of ARA-IIs
within the range of study in each method were analyzed in ﬁve
replicates during the same day (intra-day precision) and ﬁve
consecutive days (inter-day precision).
2.4.2. Recovery studies
Accuracy and the reliability of both methods were ascertained
by performing recovery experiments. To a ﬁxed amount of
drug in formulation (pre-analyzed): pure drug at three differ-
ent levels corresponding to its 80%, 100% and 120% was
added (standard addition method), and the total was found by
the proposed methods. Each test was repeated three times and
the results obtained were compared with expected results.
2.4.3. Ruggedness
Ruggedness of both methods was done at three different
concentration levels of each ARA-II within the range of study
in each method.
Ruggedness of potentiometric method was expressed as the
RSD of the same procedure applied by three different analysts
as well as using three different burettes.
The ruggedness of the UV spectroscopic method was
determined by carrying out the experiment on three different
instruments and by three different analysts.eters of ARA-IIs.
sartan Telmisartan Valsartan
296 250
4–30 2–20
970.450 0.99970.390 0.99970.560
0.036xþ0.023 Y¼0.056xþ0.023 Y¼0.0328xþ0.0206
19 0.2579 0.1337
95 0.7805 0.4052
Figure 2 Absorption spectra of angiotensin-II-receptor antagonists: (I) Eprosartan mesylate, (II) Irbesartan, (III) Valsartan and (IV)
Telmisartan.
Figure 3 Potentiometric titration curve for ARA-IIs titrated with
standardized sodium hydroxide aqueous solution ((a) Eprosartan
mesylate, (b) Irbesartan, (c) Telmisartan, and (d) Valsartan).
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2.4.4.1. Potentiometric method. For the establishment of
method linearity, ﬁve different weights of ARA-IIs test
samples corresponding to 20%,40%, 60%, 80% and 100%
of the about weight 20 mg were taken and analyzed potentio-
metrically. Calibration curve was drawn by plotting test
sample weight on X axis and titre values on Y axis. The
values of correlation coefﬁcient, slope and intercept were
determined.
2.4.4.2. UV spectroscopic method. Appropriate dilutions of
standard stock solutions of each ARA-II were analyzed as per
the developed methods. Beer–Lambert’s concentration range
and linearity data were determined.
2.4.5. LOD and LOQ
For UV method, limit of detection (LOD) and limit of
quantiﬁcation (LOQ) of each ARA-II were calculated as
3.3 @/S and 10 @/S, respectively as per ICH guidelines, where
q is the standard deviation of the response and S is the slope of
the calibration plot. The LOD is the smallest concentration of
the analyte that gives a measurable response. The LOQ is the
smallest concentration of the analyte which gives response that
can be accurately quantiﬁed.3. Results and discussion
3.1. Titrimetric measurements
3.1.1. Potentiometric determination of standard active
components
ARA-IIs were titrated direct potentiometrically in a mixture of
ethanol and water (1:1) using standardized sodium hydroxide
aqueous solution as a titrant. The titration curve of ARA-IIsshowed one well-deﬁned S-shaped stoichiometric end-point
(Fig. 3). The determination of the end points from the potentio-
metric data was carried out using the Gran’s method [46].
Table 2 gives detail about acidic centres present in ARA-IIs
which corresponds to the number of equivalent of bases required
for neutralization to have the end point. For example the end
point of telmisartan corresponded to one equivalent of base and
was related to the neutralization of one –COOH group.
The percentage of each ARA-II (chemically pure laboratory
working standard) was calculated from the potentiometric
titration data. Five successive determinations were carried
out for each ARA-II. The results are tabulated in Table 3.
As seen from the data in Table 3, the mean values obtained
by the proposed method are in good agreement with the
nominal value given for each ARA-II and furthermore the
relative standard deviations are less than 1%. This indicates
that the accuracy and the precision of this method are
satisfactory.
Table 2 Acidic centres present in ARA-IIs which take part in neutralization to have the end point.
ARA-IIs Number of active acidic centres
involved in neutralization
Site of active acidic centres
involved in neutralization
Molecular weight
Eprosartan mesylate Three (a) Phenylic–COOH 520.0
(b) Allylic–COOH
(c) Mesylate (sulphonate)
Irbesartan One (a) Tetrazole 428.5
Telmisartan One (a) –COOH 514.0
Valsartan Two (a) Tetrazole 435.0
(b) –COOH
Table 3 Titrimetric determinations of ARA-IIs which are
chemically pure laboratory working standards.
ARA-IIs Potentiometric
determination
(Mean7RSD)
(%)n
Visual titrimetric
determination
(Mean7RSD)
(%)n
Nominal
value
(%)
Eprosartan
mesylate
99.7170.45 99.7670.32 99.8
Irbesartan 99.2570.35 99.2070.44 99.3
Telmisartan 99.527 0.68 99.5470.72 99.6
Valsartan 99.4270.62 99.4570.58 99.4
nAverage of ﬁve determinations.
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components
The percentage of each ARA-II (chemically pure laboratory
working standard) was calculated from the visual titration
data. Five successive determinations were carried out for each
ARA-II. As seen from the data in Table 3, results obtained by
this method were found to be in good agreement with those
obtained by potentiometric method.3.1.3. Titrimetric determination of ARA-IIs in dosage forms
In order to evaluate the applicability of the above-mentioned
titrimetric methods to pharmaceutical preparations, ARA-IIs
were determined in their pharmaceutical preparations respec-
tively, under the same conditions as employed for the pure
anti-inﬂammatory agents. The fact that the mV values before
the end-points in the titration curves of pure anti-inﬂamma-
tory agents and their corresponding pharmaceuticals are
almost identical provides evidence that the titration curves
are not due to other excipients that might be present in the
pharmaceutical preparations and excipients do not affect the
titration curves. The excipients in the above-mentioned phar-
maceutical preparation do not include acidic substances.
Table 4 summarizes the results obtained for each anti-
inﬂammatory agent in the corresponding pharmaceuticals,
expressed as percentages of the nominal contents. The results
are in good agreement with the nominal contents and the
RSD values are less than 1%. Thus, the reproducibility and
accuracy are very satisfactory for the analysis of pharmaceu-
tical preparations as well as bulk drugs. These results indicatethat the content of each ARA-II in the pharmaceuticals can be
safely determined using titrimetric method without interfer-
ence from other substances in the preparations.
3.2. UV-spectrophotometric measurements
Lambda max, Beer’s law limit (concentration range), correlation
coefﬁcient (r) and regression equation obtained by UV-spectro-
photometric method for each ARA-II are given in Table 1. The
proposed UV-spectrophotometric method was also successfully
applied for the determination of ARA-IIs in some pharmaceutical
preparations (Table 4). The results are in good agreement with the
nominal contents and the RSD values are less than 1%. Thus, the
reproducibility and accuracy are very satisfactory for the analysis
of pharmaceutical preparations as well as bulk drugs.
3.3. Validation
3.3.1. Recovery studies
The recovery studies of standard additions to commercial
pharmaceuticals were carried out in order to determinate
accuracy and selectivity of the method. In these titrations, as
the amount of pure standard added to commercial pharma-
ceuticals increases, the volume of titrant used increases
linearly. The results related to these studies are presented in
Table 5. It can be seen from this Table that the mean
recoveries and RSD values are good evidence of the accuracy
of the method.
3.3.2. Precision
The RSD values of intra-day and inter-day precision of the
potentiometric and UV spectroscopic methods for all ARA-IIs
showed that the precision of both methods was good
(Table 6).
3.3.3. Ruggedness
The RSD values of inter analyst as well as inter instrument
analysis were less than 2% for potentiometric method as well
as UV spectrometric method. This proves good ruggedness of
the method(Table 7).
3.3.4. LOD and LOQ
For UV method, LOD and LOQ of each ARA-II are
presented in Table 1.
Table 4 Determinations of ARA-IIs in some pharmaceutical preparations by the proposed methods.
Pharmaceuticals ARA-IIs Lable claim (mg) Percent lable claim estimated (Mean7RSD) (%)
Potentiometric Visual titrimetric UV spectroscopic
Teveten Eprosartan mesylate 400 100.5170.71 100.2670.28 99.990 70.32
Karvea Irbesartan 300 100.3370.52 99.1670.42 100.1170.22
Telsartan Telmisartan 80 100.1070.42 100.5570.64 100.2770.47
Diovan Valsartan 160 99.9670.32 100.3470.46 100.6670.57
Table 5 Recovery studies by standard additions technique.
ARA-IIs Excess drug added to
the analyte (%)
Potentiometry UV spectroscopy
Recoveryn (%) RSD (%) S.E. Recoveryn (%) RSD (%) S.E.
Eprosartan mesylate 80 98.71 0.66 0.22 98.55 0.26 0.81
100 99.65 1.10 0.66 98.94 1.15 0.95
120 99.59 0.82 0.51 98.89 0.63 1.14
Irbesartan 80 99.02 0.95 0.61 99.10 1.16 1.54
100 99.15 1.12 0.34 99.16 1.19 0.69
120 99.20 0.66 0.38 99.19 1.98 1.84
Telmisartan 80 99.88 0.69 0.44 99.68 1.68 1.52
100 99.94 0.84 0.48 99.59 1.48 1.94
120 99.79 1.12 0.39 99.54 1.50 1.80
Valsartan 80 98.99 1.19 0.47 99.94 0.94 1.83
100 99.11 1.21 0.52 100.10 0.87 1.39
120 99.08 0.99 0.59 99.89 1.16 1.47
nAverage of three determinations.
Table 6 Precision of ARA-IIs by potentiometry and UV
spectroscopy.
ARA-IIsn Potentiometry (n¼5) UV spectroscopy
(n¼5)
Intra-day
(RSD)
(%)
Inter-day
(RSD)
(%)
Intra-day
(RSD)
(%)
Inter-day
(RSD)
(%)
Eprosartan
mesylate
1.20 1.05 1.59 1.46
Irbesartan 1.85 0.95 1.29 1.90
Telmisartan 1.54 1.34 1.90 1.10
Valsartan 1.45 0.92 1.16 1.55
nAverage of three concentrations of each ARA-II within the
range of study in each method.
Table 7 Ruggedness of ARA-IIs by potentiometry and
UV spectroscopy.
ARA-IIsn Potentiometry
(RSD) (%) (n¼3)
UV spectroscopy
(RSD) (%) (n¼3)
Inter-
analysts
Inter-
instruments
Inter-
analysts
Inter-
instruments
Eprosartan
mesylate
1.75 0.96 1.39 1.12
Irbesartan 1.65 1.54 1.84 1.28
Telmisartan 1.32 1.32 1.69 1.31
Valsartan 1.19 1.29 1.34 1.39
nAverage of three concentrations of each ARA-II within the
range of study in each method.
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ARA-IIs were determined in pharmaceutical preparations by
the developed methods and the results obtained are presented
in Table 4 where excellent agreement between the three
procedures can be observed. The statistical comparison of
the results shows that, there is no signiﬁcant difference
between results of UV-spectrophotometric and potentiometric
methods (t¼1.49, F¼1.16); UV-spectrophotometric andvisual titrimetric methods (t¼1.18, F¼1.33) since the calcu-
lated t- and F-tests did not exceed the theoretical values (n¼5,
p¼0.05, t¼2.23, F¼5.05) at the 95% conﬁdence level
(Table 8).
4. Conclusion
Statistical tests indicate that the proposed titrimetric and UV
methods appear to be equally suitable for routine determination
Table 8 Linearity studies for potentiometric
method only.
ARA-IIs Correlation
coefﬁcient
(r7S.D.)
Slope7S.D. Regression
equation
Eprosartan
mesylate
0.99971.120 1.2370.58 Y¼1.23xþ0.0017
Irbesartan 0.99871.190 0.0770.01 Y¼0.07xþ0.0003
Telmisartan 0.99970.960 1.6570.87 Y¼1.65xþ0.0003
Valsartan 0.99971.150 1.1370.84 Y¼1.13xþ0.0001
S.H. Patil, M.V. Janjale476of ARA-IIs in pharmaceutical formulation. As a result of this
work, ARA-IIs can now be determined titrimetrically by the
proposed method. This aqueous titrimetric assay was successfully
applied to the determination of pure authentic samples and some
of their pharmaceutical preparations. In the proposed method,
the titrations of all ARA-IIs have shown rather well shaped end-
points with high potential jumps. In conclusion, the proposed
titrimetric method could be utilized readily for routine analysis of
pharmaceuticals since the reported methods in literature survey
suffer from drawbacks such as high cost, multiple steps and time
consuming, also costly solvents (HPLC) while proposed titri-
metric method offers a simple system and with the short
analytical time, coupled with good reproducibility, accuracy,
ruggedness and cost-effectiveness.Acknowledgments
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